Study S002824

A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04838405
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 129
Start: 2021-04-29
Primary completion: 2024-06-18
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Diabetes
Interventions: DRUG:CT-388; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of Treatment-Emergent Adverse Events as assessed by self-report [Baseline up to 24 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007991	Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity. Chakravarthy MV, Molecular metabolism	2026	Randomized trial	PMID 41319798 DOI	cites ClinicalTrials.gov:NCT04838405
R0048963	125-OR: Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity ALEXANDRA STEINBERG, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04838405
R0052201	763-P: Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes ALEXANDRA STEINBERG, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04838405